or Try an Advanced Search...

    Technical Analysis for BMEA - Biomea Fusion, Inc.

    Grade Last Price % Change Price Change
    F 6.28 -2.18% -0.14
    BMEA closed down 2.18 percent on Wednesday, November 20, 2024, on 66 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical BMEA trend table...
    Date Alert Name Type % Chg
    Wide Bands Range Expansion 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Down 4 Days in a Row Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    Doji - Bullish? Reversal -2.18%
    Wide Bands Range Expansion -2.18%
    Down 3 Days in a Row Weakness -2.18%
    Oversold Stochastic Weakness -2.18%
    Wide Bands Range Expansion -2.33%
    Oversold Stochastic Weakness -2.33%
    Older End-of-Day Signals for BMEA ...

       Recent Intraday Alerts

    Alert Time
    Down 5% about 17 hours ago
    Fell Below Previous Day's Low about 17 hours ago
    Down 3% about 17 hours ago
    Down 2 % about 18 hours ago
    Possible NR7 about 18 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    BMEA Chart by TradingView
    Basic chart:

    Profile

    Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of MENIN, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was founded in 2017 and is based in Redwood City, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Cancer

    Is BMEA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 18 Late-Breaker Oral Presentation Showing New Analysis from the Escalation Portion of COVALENT-111 Presented at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)
    Nov 13 We're A Little Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate
    Oct 30 Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate
    Oct 29 Biomea Fusion GAAP EPS of -$0.91 beats by $0.04
    Oct 29 Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights
    Oct 21 Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219
    Oct 15 Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP...
    Oct 10 Morning Movers: Arcadium Lithium surges after deal to be acquired
    Oct 7 Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)
    Oct 3 Independent Director of Biomea Fusion Michael J. Hitchcock Buys 200% More Shares
    See more BMEA news...

    Comments

    T

    TraderMike over 1 year ago

    I found this on the "Calm After Storm" scan today (I also like the NR7 & Doji).  These little biotechs are always interesting after having a big pop based on some good/promising news.  The standard plan seems to be to immediately issue a secondary offering -- which BMEA did.  So now I'm looking for it to climb back above that offering price of $30 and retest the March high.

    0 Reply
    View full discussion...

    Indicators

    Indicator Value
    52 Week High 22.74
    52 Week Low 3.61
    Average Volume 840,671
    200-Day Moving Average 10.09
    50-Day Moving Average 9.45
    20-Day Moving Average 8.79
    10-Day Moving Average 7.23
    Average True Range 0.70
    RSI (14) 22.48
    ADX 35.86
    +DI 13.38
    -DI 34.72
    Chandelier Exit (Long, 3 ATRs) 10.74
    Chandelier Exit (Short, 3 ATRs) 8.15
    Upper Bollinger Bands 12.69
    Lower Bollinger Band 4.90
    Percent B (%b) 0.18
    BandWidth 88.58
    MACD Line -1.01
    MACD Signal Line -0.70
    MACD Histogram -0.3136
    Fundamentals Value
    Market Cap 224.23 Million
    Num Shares 35.7 Million
    EPS -3.33
    Price-to-Earnings (P/E) Ratio -1.89
    Price-to-Sales 0.00
    Price-to-Book 3.18
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 7.05
    Resistance 3 (R3) 7.05 6.80 6.92
    Resistance 2 (R2) 6.80 6.61 6.80 6.87
    Resistance 1 (R1) 6.54 6.48 6.42 6.54 6.83
    Pivot Point 6.29 6.29 6.23 6.29 6.29
    Support 1 (S1) 6.03 6.10 5.91 6.03 5.73
    Support 2 (S2) 5.78 5.97 5.78 5.69
    Support 3 (S3) 5.52 5.78 5.64
    Support 4 (S4) 5.52